Please login to the form below
anaemia
This page shows the latest anaemia news and features for those working in and with pharma, biotech and healthcare.
Roche reports positive results for crovalimab as rare blood disease treatment
PNH causes a patient’s red blood cells to break apart, resulting in a range of debilitating symptoms such as anaemia, fatigue, blood clots and kidney disease.
Latest news
-
Bristol Myers Squibb’s plaque psoriasis treatment recommended by CHMP
The company also received a recommendation from the CHMP this month for Reblozyl (luspatercept) as a treatment for adult patients with anaemia associated with non-transfusion-dependent beta thalassaemia.
-
bluebird bio sells second FDA priority review voucher for $95m
The clinical studies were placed on a partial hold in December 2021 relating to an investigation by bluebird bio into an adolescent patient with persistent, non-transfusion-dependent anaemia following treatment
-
FDA lifts partial clinical hold on bluebird bio’s sickle cell gene therapy studies
The clinical studies were placed on a partial hold in December 2021 relating to an investigation by bluebird into an adolescent patient with persistent, non-transfusion-dependent anaemia following treatment with ... The disease can cause serious health
-
Novartis’ iptacopan shows promise as rare blood disease treatment in phase 3 study
which can cause anaemia, thrombosis, fatigue and other debilitating symptoms that can impact quality of life. ... Study principal co-investigator, Professor Régis Peffault de Latour of Saint-Louis Hospital, Greater Paris University Hospital, said:
-
bluebird bio sells Rare Pediatric Disease Priority Review Voucher
Patients with the most severe form of the disease develop life-threatening anaemia and have to undergo regular blood transfusions, a lengthy process typically needed every two to five weeks.
More from news
Approximately 11 fully matching, plus 201 partially matching documents found.
Latest Intelligence
-
Maintaining continuity of care in Ukraine as conflict continues
With the help of WHO, Roche has shipped packs of antibiotics and batches of anaemia treatment to Poland and Ukraine.
-
A creative awakening – how pharma is bringing innovation to the patient journey
He cites recent projects on sickle cell anaemia and thalassaemia to underscore the potential.
-
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
Hyperkalaemia (elevated levels of potassium in the blood) and anaemia are both common complications of CKD, associated with poorer cardiovascular outcomes and an increased risk of hospitalisation and death. ... They also present significant lifestyle
-
Cortellis Drugs to Watch in 2020 report
4. Vadadustat is an inhibitor of hypoxiainducible factor (HIF)-prolyl hydroxylase (HIF-PH) from Akebia Therapeutics/ Mitsubishi Tanabe Pharma/Otsuka that targets anaemia in chronic kidney disease (CKD).
-
Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019
The sales forecast for Zolgensma is $2.09bn. Roxadustat, from AstraZeneca, FibroGen and Astellas, targets anaemia in chronic kidney disease (CKD). ... The drug is under regulatory review in Japan, where a filing for anaemia in CKD patients on dialysis
More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.
Latest appointments
-
New hires at FibroGen, Saniona and Turbine
anaemia that has seen little progress in the last 30 years,” said Conterno.
-
Spectrum appoints chief medical officer
of iron deficiency anaemia in adult patients with chronic kidney disease.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
If our patients are diverse, why are clinical trials so white?
In medicine, this includes transgressions such as the dehumanising 1 Tuskegee Syphilis Experiment, in which African American men were promised treatment for “bad blood” – a term which included syphilis, anaemia, and
-
All Change: The Challenges of Embracing a Plant-Based Diet
In women – especially those of childbearing age – intakes of iron are low and put women at risk of iron deficiency anaemia as indicated by low haemoglobin levels.
-
Joined-up thinking on anaemia
Iron deficiency anaemia is very common in inflammatory bowel disease (IBD) and can seriously reduce people’s quality of life, but it’s often under-treated. ... Pharmacosmos is committed to improving the lives of patients with iron deficiency anaemia.
-
Living with Crohn's disease: a patient perspective
It’s also a very individual condition. The most common symptoms are not only diarrhoea, but also tiredness and fatigue, abdominal pain, mouth ulcers, anaemia, loss of appetite, and weight loss.
-
Patient Power: Too Much of a Good Thing?
It commonly causes abdominal pain, diarrhoea, weight loss and vomiting but because it affects the immune system it can cause other problems such as anaemia, arthritis, lack of concentration, tiredness and
More from PMHub
Approximately 1 fully matching, plus 5 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Manager
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- Rare diseases: not so rare after all
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- NHS England announces rare genetic disorder fast-tracking service
- NICE sees ‘promise’ in four UTI tests that could help in fight against AMR
- Connectome competitiveness
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Trust me, I’m from pharma
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- Sobi’s Kineret granted FDA Emergency Use Authorisation for COVID-19 related pneumonia
PMHub
The Good Ideas Group
Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
